Voriconazole
Voriconazole is an azole antifungal used to treat serious fungal infections, including invasive aspergillosis, Candida infections (candidemia, deep tissue Candida infections and esophageal candidiasis), and infections caused by Scedosporium and Fusarium.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 28 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Voriconazole (Vfend) is a strong azole antifungal for serious infections such as invasive aspergillosis (a dangerous mold infection), candidemia (yeast in the bloodstream) and esophageal candidiasis; it blocks the enzyme fungi use to make ergosterol, a key part of their cell wall, and is a usual first choice for aspergillosis, on the market since about 2002 and available generically. Many people notice brief vision changes (blurring, light sensitivity, altered colors), and nausea, headache and rash are common too. The one thing to watch for is liver trouble, such as yellowing skin or eyes, so your liver tests are checked before and during treatment.
Clinical pearls
- Take the tablets or liquid on an empty stomach, away from meals, since high-fat food lowers how much your body absorbs.
- Low potassium, magnesium or calcium should be corrected before starting, because voriconazole can disturb heart rhythm (QT prolongation).
- Rifampin, carbamazepine and St. John’s Wort drop its levels too low to work, so list every medicine and supplement you take.
- Use high-SPF sunscreen and cover up outdoors; with long-term use, sun-related skin reactions have been linked to skin cancer.
Patient information guide A plain-language walkthrough of Voriconazole, written from its FDA label.
What Voriconazole is used for
▾
Voriconazole treats several serious fungal infections. Product details vary.
- Invasive aspergillosis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections (skin, abdomen, kidney, bladder wall and wounds)
- Esophageal candidiasis (labeled for the Vfend and voriconazole tablet, oral suspension and injection products in the evidence, but not for the Voriconazole for injection product)
- Serious infections from Scedosporium apiospermum and Fusarium species, in patients intolerant of or refractory to other therapy
- Age ranges differ: some tablet and injection products are labeled for ages 12 to 14 weighing at least 50 kg and for ages 15 and older, while others are labeled for ages 2 and older
How Voriconazole works
▾
Voriconazole is an azole antifungal. It blocks a fungal enzyme involved in making ergosterol, an essential part of the fungal cell wall. As ergosterol is lost and other sterols build up, the fungus is damaged and cannot grow normally.
Voriconazole dosage
▾
Voriconazole is given as an IV infusion, a tablet or an oral suspension, usually every 12 hours. IV treatment may start with a loading dose.
- High-fat meals reduce absorption of the tablets and suspension, so ask about timing with food
- Dose changes may be needed for low body weight, liver impairment or certain interacting medicines
- Follow your prescriber and the product label, and ask your pharmacist what to do about a missed dose
Dosing details from the FDA-approved label
From the Voriconazole prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Invasive Aspergillosis
- Loading: 6 mg/kg every 12 hours for the first 24 hours (intravenous infusion)
- Maintenance: 4 mg/kg every 12 hours intravenous infusion
- 200 mg every 12 hours oral tablets
- 5 mL every 12 hours oral suspension
- Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours
- Candidemia in nonneutropenics and other deep tissue Candida infections
- Loading: 6 mg/kg every 12 hours for the first 24 hours (intravenous infusion)
- Maintenance: 3–4 mg/kg every 12 hours intravenous infusion
- 200 mg every 12 hours oral tablets
- 5 mL every 12 hours oral suspension
- Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours
- Scedosporiosis and Fusariosis
- Loading: 6 mg/kg every 12 hours for the first 24 hours (intravenous infusion)
- Maintenance: 4 mg/kg every 12 hours intravenous infusion
- 200 mg every 12 hours oral tablets
- 5 mL every 12 hours oral suspension
- Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours
- Esophageal Candidiasis
- Loading dose and intravenous maintenance: Not Evaluated
- Oral maintenance: 200 mg every 12 hours tablets
- 5 mL every 12 hours oral suspension
- Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours
- Adults with mild to moderate hepatic impairment (Child-Pugh Class A and B)
- Use half the maintenance dose
- Hepatic impairment
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Dosage in Adults ( 2.3 ) Infection Loading dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Oral suspension Invasive Aspergillosis 6 mg/kg every 12 hours for the first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Candidemia in nonneutropenics and other deep tissue Candida infections 3–4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Scedosporiosis and Fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours 5 mL every 12 hours Esophageal Candidiasis Not Evaluated Not Evaluated 200 mg every 12 hours 5 mL every 12 hours o Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours o Hepatic Impairment : Use half the maintenance dose in adult patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) ( 2.5 ) o Renal Impairment : Avoid intravenous administration in adult patients with moderate to severe renal impairment (creatinine clearance <50 mL/min) ( 2.6 ) • Dosage in Pediatric Patients 2 years of age and older ( 2.4 ) o For pediatric patients 2 to less than 12 years of age and 12 to 14 years of age weighing less than 50 kg see Table below. Infection Loading Dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Oral suspension Invasive Aspergillosis 9 mg/kg every 12 hours for the first 24 hours 8 mg/kg every 12 hours after the first 24 hours 9 mg/kg every 12 hours (maximum dose of 350 mg every 12 hours) 0.225 mL/kg every 12 hours [maximum dose of 8.75 mL (350 mg) every 12 hours] Candidemia in nonneutropenics and other deep tissue Candida infections Scedosporiosis and Fusariosis Esophageal Candidiasis Not Evaluated 4 mg/kg every 12 hours 9 mg/kg every 12 hours (maximum dose of 350 mg every 12 hours) 0.225 mL/kg every 12 hours [maximum dose of 8.75 mL (350 mg) every 12 hours] o For pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight use adult dosage.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Voriconazole side effects
▾
Common side effects seen in adults include:
Common side effects
- Vision changes (blurred vision, light sensitivity, color changes)
- Fever and chills
- Nausea and vomiting
- Rash
- Headache
- Abnormal liver tests
- Fast heartbeat
- Hallucinations
When to get medical help
- Yellowing of skin or eyes, or other signs of liver problems
- Fast, irregular or pounding heartbeat, fainting, or dizziness
- Flushing, chest tightness, trouble breathing, or faintness during an IV infusion
- Blistering, peeling skin, or a widespread severe rash
- Vision problems that last or get worse, especially if treatment goes beyond 28 days
- Severe sunburn-like reactions or any new or changing skin lesion
- Signs of Cushing’s syndrome or adrenal insufficiency, especially if you take corticosteroids
- Bone or skeletal pain during long-term use
Call your doctor promptly for signs of liver problems, heart rhythm changes, severe skin reactions, lasting vision changes or infusion reactions.
Voriconazole warnings and precautions
▾
- Liver toxicity: serious liver reactions have occurred, so liver tests are monitored.
- Heart rhythm: QT prolongation and arrhythmias can occur; electrolytes should be corrected.
- Vision: vision should be monitored if treatment goes beyond 28 days.
- Skin: severe skin reactions and sun sensitivity can occur, and skin cancers have been reported with long-term use.
- Other risks: kidney problems, pancreatitis, adrenal problems, bone problems and fetal harm.
Voriconazole interactions
▾
Voriconazole is broken down by liver enzymes and also blocks them, so many drugs interact.
- Rifampin, rifabutin, carbamazepine, long-acting barbiturates and St. John’s Wort lower voriconazole levels
- Pimozide, quinidine and ivabradine raise heart rhythm risk
- Sirolimus, ergot alkaloids, naloxegol, tolvaptan, lurasidone, finerenone, eplerenone and voclosporin can reach unsafe levels
- Efavirenz and ritonavir can change levels of both drugs
- Cyclosporine, methadone, fentanyl, phenytoin and fluconazole may need dose changes or monitoring
Interactions listed in the FDA-approved label
From the Voriconazole prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Rifampin and Rifabutin: Significantly reduced voriconazole plasma exposure (CYP450 induction); rifabutin exposure is also significantly increased by voriconazole. Contraindicated
- Efavirenz (400 mg every 24 hours): Significantly reduced voriconazole exposure; efavirenz exposure significantly increased. Contraindicated
- Efavirenz (300 mg every 24 hours): Slight decrease in voriconazole AUC τ; slight increase in efavirenz AUC τ. Increase voriconazole oral maintenance dose to 400 mg every 12 hours and decrease efavirenz to 300 mg every 24 hours.
- High-dose Ritonavir (400 mg every 12 hours): Significantly reduced voriconazole exposure; no significant effect of voriconazole on ritonavir Cmax or AUC τ. Contraindicated
- Low-dose Ritonavir (100 mg every 12 hours): Reduced voriconazole exposure; slight decrease in ritonavir Cmax and AUC τ. Avoid concomitant administration unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
- Carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital): Not studied, but likely to result in significant reduction of voriconazole exposure (CYP450 induction). Contraindicated
- Phenytoin: Significantly reduced voriconazole exposure (CYP450 induction). Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV every 12 hours or from 200 mg to 400 mg orally every 12 hours (100 mg to 200 mg orally every 12 hours in patients weighing less than 40 kg).
- St. John's Wort: Significantly reduced voriconazole exposure (CYP450 inducer; P-gp inducer). Contraindicated
- Sirolimus: Sirolimus exposure is significantly increased by voriconazole (CYP3A4 inhibition). Contraindicated
- Fluconazole: Significantly increased voriconazole exposure (CYP2C9, CYP2C19 and CYP3A4 inhibition). Avoid concomitant administration; start monitoring for adverse reactions and toxicity related to voriconazole within 24 hours after the last dose of fluconazole.
Read the label’s full interactions text
5.1 Hepatic Toxicity In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly hematological malignancy). Hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy [see Adverse Reactions ( 6.1 )] . A higher frequency of liver enzyme elevations was observed in the pediatric population [see Adverse Reactions ( 6.1 )] . Hepatic function should be monitored in both adult and pediatric patients. Measure serum transaminase levels and bilirubin at the initiation of voriconazole therapy and monitor at least weekly for the first month of treatment. Monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are noted. If liver function tests become markedly elevated compared to baseline, voriconazole should be discontinued unless the medical judgment of the benefit/risk of the treatment for the patient justifies continued use [see Dosage and Administration ( 2.5 ) and Adverse Reactions ( 6.1 )].
7 DRUG INTERACTIONS Voriconazole is metabolized by cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Therefore, inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively. Voriconazole is a strong inhibitor of CYP3A4, and also inhibits CYP2C19 and CYP2C9. Therefore, voriconazole may increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes. Tables 10 and 11 provide the clinically significant interactions between voriconazole and other medical products.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Voriconazole
▾
- Tell your prescriber about allergies to voriconazole or other azoles
- Mention liver, kidney or heart rhythm problems and low potassium, magnesium or calcium
- Pregnancy: voriconazole can harm an unborn baby, and effective contraception is advised
- Breastfeeding: discuss with your prescriber
- Children under 2 years: not recommended; some products have higher age limits
- Older adults: levels are higher but no dose change is recommended for age alone
- Tablets contain lactose
Voriconazole overdose
▾
In clinical trials, three children accidentally received up to five times the recommended IV dose. One brief episode of light sensitivity was reported. There is no known antidote, and hemodialysis may help remove voriconazole from the body.
What Voriconazole does in the body
▾
Higher voriconazole blood levels were linked to more liver test abnormalities and vision problems. A link between blood levels and effectiveness was not detected in the analysis of 6 of 10 trials. At very high single doses, voriconazole increased the QTc interval, a measure of heart rhythm timing.
How your body processes Voriconazole
▾
Voriconazole is well absorbed by mouth, with about 96% bioavailability, and peaks 1 to 2 hours after a dose. High-fat meals reduce absorption. It is broken down mainly by liver enzymes (CYP2C19, CYP2C9 and CYP3A4), and less than 2% leaves unchanged in urine. Because the body handles it non-linearly, a modest dose increase can raise levels much more than expected.
How to store Voriconazole
▾
stored at 15°C to 30°C (59°F to 86°F) . times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C (36°F to 46°F). stored at 2°C to 8°C (36°F to 46° F) (in a refrigerator) before reconstitution.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Voriconazole
205 supplements and herbal products have documented interactions with Voriconazole in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 6
- Moderate · 159
- Minor · 40
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Voriconazole: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Voriconazole — the kind of thing our pharmacy team would talk through with you at the counter.
What is voriconazole used for?
▾
How should I take it?
▾
What side effects are common?
▾
When should I call my doctor right away?
▾
Do I need to worry about the sun?
▾
Can I take it with my other medicines?
▾
Is Voriconazole available over the counter?
▾
When was Voriconazole first available?
▾
Who makes Voriconazole?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Voriconazole on HelloPharmacist
Voriconazole forms and strengths (how it comes)
Voriconazole is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Voriconazole inactive ingredients by manufacturer.
Tablet
How this form is used
- Vfend tablets are labeled for invasive aspergillosis, candidemia and other deep tissue Candida infections, esophageal candidiasis, and Scedosporium and Fusarium infections
- Some voriconazole tablet products are labeled for ages 12 to 14 weighing at least 50 kg and for ages 15 and older; other voriconazole tablet products are labeled for ages 2 and older
- Vfend tablets are generally taken every 12 hours
- High-fat meals lowered absorption of voriconazole tablets, so ask your pharmacist how to time doses around food
- Vfend tablets contain lactose and should not be given to people with certain hereditary galactose problems
Injection
How this form is used
- Vfend is labeled for invasive aspergillosis, candidemia in non-neutropenic patients and other deep tissue Candida infections, and esophageal candidiasis
- Vfend is labeled for serious Scedosporium apiospermum and Fusarium infections in patients intolerant of or refractory to other therapy
- Voriconazole for injection (intravenous) is labeled for invasive aspergillosis, candidemia in non-neutropenic patients and other deep tissue Candida infections, and Scedosporium and Fusarium infections
- Vfend is given as an intravenous infusion, often with a loading dose followed by twice-daily maintenance dosing
- Voriconazole injection can cause infusion reactions (flushing, fever, chest tightness, trouble breathing); tell the care team right away if these occur
Oral suspension
How this form is used
- Vfend oral suspension is labeled for invasive aspergillosis, candidemia and other deep tissue Candida infections, esophageal candidiasis, and Scedosporium and Fusarium infections
- Voriconazole for oral suspension is labeled for the same set of infections in people 2 years and older
- Vfend oral suspension is generally taken every 12 hours
- High-fat meals lowered absorption of voriconazole oral suspension, so ask your pharmacist how to time doses around food
Voriconazole on the U.S. market: products, makers and brands
How Voriconazole appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
33 companies list 57 Voriconazole product records with the FDA, mostly as tablet, injection, oral suspension; the earliest marketing or approval year on record is 2002. Brand names on the directory include Vfend; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (22) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Voriconazole is used (Medicaid data)
A general measure of how commonly Voriconazole is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Voriconazole is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Voriconazole prescribed? Of the 1,601 medications we measure, Voriconazole ranks #1,012 by Medicaid prescriptions — more than 37% of them.
Utilization by Voriconazole product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
voriconazole 200 MG Oral Tablet Most dispensed
Summed across the 7 of 58 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349434
voriconazole 40 MG/ML Oral Suspension
Summed across the 5 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 465355
voriconazole 200 MG Injection
Summed across the 5 of 16 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 351209
voriconazole 50 MG Oral Tablet
Summed across the 4 of 48 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349435
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Voriconazole, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 21 of 132 listed Voriconazole NDCs with Medicaid activity.
Compare Voriconazole products
A representative set of FDA-listed product records for Voriconazole — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mg/mL | Intravenous | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Civica, Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Fosun Pharma USA Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Hainan Poly Pharm. Co., Ltd. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Meitheal Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | PAI Holdings, LLC dba PAI Pharma | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Roerig × 2 listings | NDA | View NDC → |
| 10 mg/mL | Intravenous | Sandoz Inc | ANDA | View NDC → |
| 200 mg | Intravenous | Slate Run Pharmaceuticals | ANDA | View NDC → |
| 10 mg/mL | Intravenous | UBI Pharma Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Xellia Pharmaceuticals USA LLC | NDA | View NDC → |
| 💊Oral suspension | ||||
| 40 mg/mL | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 40 mg/mL | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 40 mg/mL | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 40 mg/mL | Oral | Mylan Pharmaceuticals Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 40 mg/mL | Oral | Novel Laboratories, Inc. | ANDA | View NDC → |
| 40 mg/mL | Oral | Roerig | NDA | View NDC → |
| 40 mg/mL | Oral | Slate Run Pharmaceuticals, LLC | ANDA | View NDC → |
| 40 mg/mL | Oral | Zhejiang Poly Pharm Co., Ltd. | ANDA | View NDC → |
| 💊Tablet | ||||
| 50 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 200 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 50 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 200 mg | Oral | American Health Packaging × 2 listings | ANDA | View NDC → |
| 50 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 200 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 200 mg | Oral | AvPAK | ANDA | View NDC → |
| 200 mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 50 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 200 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 50 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 200 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 50 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 200 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 50 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 200 mg | Oral | Mylan Institutional Inc. | ANDA | View NDC → |
| 50 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 200 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 50 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 200 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 200 mg | Oral | Roerig | NDA | View NDC → |
| 50 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 200 mg | Oral | Safecor Health LLC | ANDA | View NDC → |
| 50 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 200 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 50 mg | Oral | Solco Healthcare U.S., LLC | ANDA | View NDC → |
| 200 mg | Oral | Solco Healthcare U.S., LLC | ANDA | View NDC → |
| 50 mg | Oral | Viona Pharmaceuticals Inc | ANDA | View NDC → |
| 200 mg | Oral | Viona Pharmaceuticals Inc | ANDA | View NDC → |
| 50 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 200 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
Showing 57 of 57 products — FDA National Drug Code Directory. See every product, package size and price: browse all 57 Voriconazole NDCs →
Voriconazole side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Voriconazole — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Voriconazole are drug interaction, death, pyrexia; about 92% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Voriconazole in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Voriconazole FDA approval history
How Voriconazole went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Voriconazole was first approved by the FDA in 2002 (Brand: VFEND · Pf Prism Cv); the first generic version was approved in 2010. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Voriconazole recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 3 Voriconazole recalls since July 2021, covering 4 product listings. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Voriconazole Tablets 50mg, 30-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, M… Lots: Lot # 17231045, exp. date Apr-25 FDA record D-0319-2025 →
- Voriconazole Tablets 200 mg, 30-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA,… Lots: Lot # 17230853, exp. date Mar-25 17231271, exp. date May-25 17231300, exp. date May-25 17242050, exp. date Oct-26 17231046, exp. date Apr-25 17241156, exp. date Jun-26 17241388, exp. date Jul-26 17241800, exp. date Sep-26 FDA record D-0318-2025 →
- Voriconazole Tablets, 50 mg, packaged in cartons of 3 blister cards with 10 individual blistered doses (30 Unit Dose per carton), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43… Lots: Lot # 1014138, Exp 04/30/2025 FDA record D-0307-2025 →
- Voriconazole for Oral Suspension, 40mg/mL, Orange-Flavored, 49g/75mL when reconstituted. Mixing Directions: Tap the bottle to release the powder. Add 50mL of water to the bottle and shake vigorously… Lots: Lot#: S200756; Exp. 10/2024 Lot#: S300218; Exp. 04/2025 Lot#: S300633; Exp. 09/2025 FDA record D-0337-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 121243 3 dose forms · 5 strengths
-
Dose form (SCDF) Injection RxCUI 1727280In current FDA listings -
Dose form (SCDF) Oral Suspension RxCUI 477141In current FDA listingsClinical drug / strength (SCD) 40 MG/MLRxCUI 465355 -
Dose form (SCDF) Oral Tablet RxCUI 378691In current FDA listings
Look up RxCUI 121243 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Voriconazole supply and shortage status
Whether Voriconazole is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Voriconazole is not in shortage right now; the FDA has 1 past shortage record for it.
✅No current shortage of Voriconazole on recordRead the full Voriconazole shortage page — affected NDCs, other makers, and what to do →
Source: openFDA, from the FDA Drug Shortages database.
💵 What Voriconazole costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 200 mg | $1.88 per tablet | NDC details & price history |
| Tablet · Oral | 50 mg | $0.827 per tablet | NDC details & price history |
| Tablet, Coated · Oral | 200 mg | $1.88 per tablet | NDC details & price history |
| Tablet, Coated · Oral | 50 mg | $0.827 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Voriconazole brand names
Voriconazole is sold under one brand name in the FDA directory — Vfend. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Voriconazole: manufacturers and labelers
33 companies list Voriconazole products with the FDA. By number of product records, the largest are Roerig, American Health Packaging, Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 9 more on the FDA NDC directory.
Voriconazole drug class (RxNorm)
Voriconazole belongs to the Azole Antifungal class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Voriconazole page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Roerig is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →